Skip to content

Effect of Polysaccharide-based Complex Administration on the Gut Microbiome and Cardio-Metabolic Profile in Children With Obesity and Metabolic Syndrome.

Effect of Polysaccharide-based Complex Administration on the Gut Microbiome and Cardio-Metabolic Profile in Children With Obesity and Metabolic Syndrome.

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07321184
Acronym
Polymets
Enrollment
36
Registered
2026-01-06
Start date
2022-02-01
Completion date
2024-11-30
Last updated
2026-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Childhood Obesity

Keywords

childhood obesity, gut microbiota, metabolic syndrome, mediterranean diet, fiber

Brief summary

Childhood obesity is a growing public health concern and is associated with long-term health issues. Changing lifestyle habits, especially improving diet and maintaining these changes over time, can be challenging for children and families. For this reason, new treatment options are being explored, including ways to improve the gut microbiota, which can influence appetite and host metabolic health. This study will investigate the impact of a medical device made of polysaccharide-based complex together with healthy lifestyle and dietary intervention, on gut microbiota composition and metabolic health in children and adolescents with metabolically unhealthy obesity. The study will last 8 months and will include 3 visits: at the start (T0), after 4 months (T1), and after 8 months (T2). From T0 to T1, participants will receive the polysaccharide-based complex along with Mediterranean-style dietary and behavioral intervention. From T1 to T2, only the dietary-lifestyle program will continue. At each visit, researchers will collect blood samples, perform nutritional and body composition assessment, and collect stool samples to characterise the gut microbiota. The primary aim is to evaluate the effect on gut microbiota composition of a polysaccharide-based complex administration combined with dietary and lifestyle interventions. Furthermore, the study aims to evaluate the effectiveness of this intervention in improving obesity-related parameters and the overall cardiometabolic profile.

Interventions

DEVICEPolysaccharide-based complex

The Polysaccharide-based complex is a medical device composed of mixture of soluble and insoluble fibres (cellulose, hemicellulose, pectin, mucilages). After enrolment at T0, participants were instructed to consume a polysaccharide-based complex for 4 months at a dosage of two sachets daily, to be consumed one before lunch and one before dinner (total 5 g/day).

Sponsors

ASST Fatebenefratelli Sacco
CollaboratorOTHER
University of Milan
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
8 Years to 14 Years
Healthy volunteers
No

Inclusion criteria

* age 8 to 14 years; * obesity defined as BMI z-score ≥+2 standard deviation scores (SDS) based on the WHO growth charts * gestational age 37-42 weeks; * birth weight \>2500 g and \<4000 g; * established condition of MUO, defined as follows: 1. for children ≤10 years according to the IDEFICS criteria \[waist circumference (WC) ≥90th percentile and ≥1 of the followings triglycerides (TG) ≥90th percentile, HDL cholesterol (HDL) ≤10th percentile, systolic blood pressure (SBP) or diastolic blood pressure (DBP) ≥90th percentile, HOMA-insulin resistance ≥90th percentile or fasting glucose ≥90th percentile\]; 2. for children \>10 years according to the IDF criteria \[WC ≥ 90th percentile and ≥1 of the followings TG ≥ 150 mg/Dl, HDL ≤ 40 mg/dL, SBP ≥ 130 mmHg, DBP ≥ 85 mmHg and fasting blood glucose ≥ 100 mg/dl or known Type 2 Diabetes\]

Exclusion criteria

* diagnosis of secondary obesity; * treatment with pre/probiotics in the previous 3 months; * antibiotic treatment in the previous 3 months; * presence of chronic or acute intestinal disease in the previous 3 months

Design outcomes

Primary

MeasureTime frameDescription
gut microbiota compositionAt enrollment (T0), after 4 months (T1), at the end of the study at 8 months (T2)Collection of fecal samples, bacterial DNA extraction and analysis of V3-V4 hypervariable regions of the prokaryotic 16S ribosomal RNA (rRNA) gene

Secondary

MeasureTime frameDescription
Diastolic blood pressureAt enrollment (T0), after 4 months (T1), at the end of the study at 8 months (T2)Diastolic blood pressure measured in millimeters of mercury using a calibrated sphygmomanometer. Unit of Measure: mmHg
Macronutrient intake (grams/day)At enrollment (T0), after 4 months (T1), at the end of the study at 8 months (T2)Daily intake of macronutrients expressed in grams per day, including: * carbohydrates, * sugars, * total dietary fibers, * insoluble fibers, * soluble fibers, * proteins, * animal proteins, * plant proteins, * total lipids, * saturated fatty acids, * monounsaturated fatty acids, * polyunsaturated fatty acids, Each macronutrient will be analyzed and reported separately. Unit of Measure: g/day
Macronutrient intake (% of energy)At enrollment (T0), after 4 months (T1), at the end of the study at 8 months (T2)Contribution of macronutrients to total energy intake expressed as percentage of energy, including: * carbohydrates, * sugars, * proteins, * total lipids, * saturated fatty acids, * monounsaturated fatty acids, * polyunsaturated fatty acids, * omega-3 fatty acids, * omega-6 fatty acids. Each macronutrient will be analyzed and reported separately. Unit of Measure: % of daily energy intake (%En)
Micronutrients (µg/day)At enrollment (T0), after 4 months (T1), at the end of the study at 8 months (T2)Daily intake of vitamin B12 and folic acid expressed in micrograms per day. Unit of Measure: µg/day
Micronutrients (mg/day)At enrollment (T0), after 4 months (T1), at the end of the study at 8 months (T2)Daily intake of calcium, iron, zinc, and magnesium expressed in milligrams per day. Unit of Measure: mg/day
KIDMED scoreAt enrollment (T0), after 4 months (T1), at the end of the study at 8 months (T2)Adherence to the Mediterranean diet assessed using the KIDMED questionnaire (score range 0-12). Unit of Measure: score
Body WeightAt enrollment (T0), after 4 months (T1), at the end of the study at 8 months (T2)Body weight Description: Body weight measured in kilograms using a calibrated scale. Unit of Measure: kg
HeightAt enrollment (T0), after 4 months (T1), at the end of the study at 8 months (T2)Height Description: Standing height measured using a stadiometer. Unit of Measure: cm
Height z-scoreAt enrollment (T0), after 4 months (T1), at the end of the study at 8 months (T2)Height z-score Description: Height-for-age z-score calculated according to reference growth charts. Unit of Measure: z-score
Body Mass IndexAt enrollment (T0), after 4 months (T1), at the end of the study at 8 months (T2)Body Mass Index (BMI) Description: weight and height will be combined to report BMI in kg/m\^2 Unit of measure: kg/m\^2
Body Mass Index z-scoreAt enrollment (T0), after 4 months (T1), at the end of the study at 8 months (T2)BMI z-score Description: BMI-for-age z-score calculated according to reference growth charts. Unit of Measure: z-score
Waist circumferenceAt enrollment (T0), after 4 months (T1), at the end of the study at 8 months (T2)Waist circumference Description: : Waist circumference measured in centimeters using a non-elastic measuring tape. Unit of Measure: cm
Waist-to-height ratioAt enrollment (T0), after 4 months (T1), at the end of the study at 8 months (T2)Waist-to-height ratio Description: : Waist-to-height ratio calculated as waist circumference divided by height. Unit of Measure: unitless ratio
Fat mass (kg)At enrollment (T0), after 4 months (T1), at the end of the study at 8 months (T2)Total body fat mass expressed in kilograms, assessed using air plethysmography. Unit of Measure: kg
Fat mass (%)At enrollment (T0), after 4 months (T1), at the end of the study at 8 months (T2)Percentage of total body fat relative to body weight, assessed using air plethysmography. Unit of Measure: %
Fat free mass (kg)At enrollment (T0), after 4 months (T1), at the end of the study at 8 months (T2)Total fat-free mass expressed in kilograms, assessed using air plethysmography. Unit of Measure: kg
Fat free mass (%)At enrollment (T0), after 4 months (T1), at the end of the study at 8 months (T2)Percentage of fat-free mass relative to body weight, assessed using air plethysmography. Unit of Measure: %
Systolic blood pressureAt enrollment (T0), after 4 months (T1), at the end of the study at 8 months (T2)Systolic blood pressure measured in millimeters of mercury using a calibrated sphygmomanometer. Unit of Measure: mmHg
Fasting glucoseAt enrollment (T0), after 4 months (T1), at the end of the study at 8 months (T2)Fasting plasma glucose concentration measured in venous blood samples. Unit of Measure: mg/dL
Fasting insulinAt enrollment (T0), after 4 months (T1), at the end of the study at 8 months (T2)Fasting plasma insulin concentration measured in venous blood samples. Unit of Measure: µU/mL
Glycated hemoglobin (HbA1c)At enrollment (T0), after 4 months (T1), at the end of the study at 8 months (T2)Glycated hemoglobin (HbA1c) concentration measured in whole blood as an indicator of long-term glycemic control. Unit of Measure: mmol/mol
Lipid profileAt enrollment (T0), after 4 months (T1), at the end of the study at 8 months (T2)Fasting serum lipid concentrations including total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides. Each lipid parameter will be analyzed and reported separately. Unit of Measure: mg/dL
Liver enzymesAt enrollment (T0), after 4 months (T1), at the end of the study at 8 months (T2)Serum liver enzyme concentrations including aspartate aminotransferase (AST) and alanine aminotransferase (ALT). Each enzyme will be analyzed and reported separately. Unit of Measure: U/L
Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)At enrollment (T0), after 4 months (T1), at the end of the study at 8 months (T2)Insulin resistance assessed using the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), calculated from fasting plasma glucose and fasting plasma insulin concentrations. Unit of Measure: index value
Quantitative Insulin Sensitivity Check Index (QUICKI)At enrollment (T0), after 4 months (T1), at the end of the study at 8 months (T2)Insulin sensitivity assessed using the Quantitative Insulin Sensitivity Check Index (QUICKI), calculated from fasting plasma glucose and fasting plasma insulin concentrations. Unit of Measure: index value
Triglyceride-Glucose (TyG) indexAt enrollment (T0), after 4 months (T1), at the end of the study at 8 months (T2)Insulin resistance assessed using the Triglyceride-Glucose (TyG) index, calculated from fasting triglyceride and fasting plasma glucose concentrations. Unit of Measure: index value
Atherogenic Index of Plasma (AIP)At enrollment (T0), after 4 months (T1), at the end of the study at 8 months (T2)Atherogenic risk assessed using the Atherogenic Index of Plasma (AIP), calculated as the logarithm of the ratio between triglycerides and HDL cholesterol concentrations. Unit of Measure: index value
Energy IntakeAt enrollment (T0), after 4 months (T1), at the end of the study at 8 months (T2)Energy intake Unit: kcal/day

Other

MeasureTime frameDescription
Triceps skinfold thicknessAt enrollment (T0), after 4 months (T1), at the end of the study at 8 months (T2)Triceps skinfold thickness measured in millimeters using a calibrated skinfold caliper.. Unit of Measure: mm
Triceps skinfold thickness z-scoreAt enrollment (T0), after 4 months (T1), at the end of the study at 8 months (T2)Triceps skinfold thickness-for-age z-score calculated according to reference growth standards. Unit of Measure: z-score
Presence of MASLDAt enrollment (T0), after 4 months (T1), at the end of the study at 8 months (T2)Description: Presence of metabolic dysfunction-associated steatotic liver disease (MASLD) assessed by abdominal ultrasound. Measure Type: Dichotomous (Yes/No)
Mid-upper arm circumference (MUAC)At enrollment (T0), after 4 months (T1), at the end of the study at 8 months (T2)Mid-upper arm circumference (MUAC) Description: : Mid-upper arm circumference measured in centimeters using a non-elastic measuring tape. Unit of Measure: cm
Mid-upper arm circumference (MUAC) z-scoreAt enrollment (T0), after 4 months (T1), at the end of the study at 8 months (T2)Mid-upper arm circumference (MUAC) z-score Description: Mid-upper arm circumference-for-age z-score calculated according to reference growth standards. Unit of Measure: z-score

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026